Combination chelation therapy

被引:7
作者
Aydinok, Yesim [1 ,2 ]
机构
[1] Ege Univ, Sch Med, Dept Pediat Hematol, Izmir, Turkiye
[2] Ege Univ, Sch Med, Dept Pediat Hematol, TR-35100 Izmir, Turkiye
关键词
deferasirox; deferiprone; deferoxamine; iron chelation; iron overload; thalassemia; BETA-THALASSEMIA MAJOR; RANDOMIZED CONTROLLED-TRIAL; INTRACELLULAR LABILE IRON; RAT-HEART CELLS; MYOCARDIAL IRON; DEFERIPRONE TREATMENT; HYPERTRANSFUSED RATS; OVERLOADED PATIENTS; DEFERASIROX ICL670; CHELATABLE IRON;
D O I
10.1111/nyas.15052
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Combination chelation therapies are considered in transfusion-dependent thalassemia patients for whom monotherapy regimens have failed to achieve iron balance or intensification of iron chelation therapy is required for the rapid reduction of excess iron to avoid permanent organ damage. Combination chelation may provide a more flexible approach for individualizing chelation therapy, thereby improving tolerability, adherence, and quality of life. In principle, iron chelators can be combined with an infinite number of dosing regimens; these involve simultaneous or sequential exposure to the chelators on the same day or alternating the drugs on different days. Clinical studies have established the safety and efficacy of chelation combinations. However, real-life data with combination therapies indicate the significance of compliance for a meaningful reduction in iron overload compared to monotherapies.
引用
收藏
页码:33 / 41
页数:9
相关论文
共 78 条
[1]   Efficacy and safety of combined oral iron chelation therapy with deferasirox and deferiprone in a patient with beta-thalassemia major and persistent iron overload [J].
Alavi, Samin ;
Sadeghi, Elham ;
Ashenagar, Azin .
BLOOD RESEARCH, 2014, 49 (01) :72-73
[2]   Effectiveness and safety of combined iron-chelation therapy with deferoxamine and deferiprone [J].
Alymara, V ;
Bourantas, D ;
Chaidos, A ;
Bouranta, P ;
Gouva, M ;
Vassou, A ;
Tzouvara, E ;
Bourantas, KL .
HEMATOLOGY JOURNAL, 2004, 5 (06) :475-479
[3]   Myocardial iron clearance during reversal of siderotic cardiomyopathy with intravenous desferrioxamine: a prospective study using T2*cardiovascular magnetic resonance [J].
Anderson, LJ ;
Westwood, MA ;
Holden, S ;
Davis, B ;
Prescott, E ;
Wonke, B ;
Porter, JB ;
Walker, JM ;
Pennell, DJ .
BRITISH JOURNAL OF HAEMATOLOGY, 2004, 127 (03) :348-355
[4]   Sequential use of deferiprone and desferrioxamine in primary school children with thalassaemia major in Turkey [J].
Aydinok, Y ;
Nisli, G ;
Kavakli, K ;
Coker, C ;
Kantar, M ;
Çetingül, N .
ACTA HAEMATOLOGICA, 1999, 102 (01) :17-21
[5]   A randomized controlled 1-year study of daily deferiprone plus twice weekly desferrioxamine compared with daily deferiprone monotherapy in patients with thalassemia major [J].
Aydinok, Yesim ;
Ulger, Zulal ;
Nart, Deniz ;
Terzi, Aysen ;
Cetiner, Nurten ;
Ellis, Gareth ;
Zimmermann, Arthur ;
Manz, Chantal .
HAEMATOLOGICA, 2007, 92 (12) :1599-1606
[6]   A randomized controlled trial comparing the combination therapy of deferiprone (DFP) and desferrioxamine (DFO) versus DFP or DFO monotherapy in patients with thalassemia major. [J].
Aydinok, Yesim ;
El-Beshlawy, Amal ;
von Orelli-Leber, Claudia ;
Czamecki-Tarabishi, Claudia ;
Manz, Chantal Y. .
BLOOD, 2006, 108 (11) :168A-168A
[7]   Iron Chelation Therapy as a Modality of Management [J].
Aydinok, Yesim .
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2018, 32 (02) :261-+
[8]   Effects of deferasirox-deferoxamine on myocardial and liver iron in patients with severe transfusional iron overload [J].
Aydinok, Yesim ;
Kattamis, Antonis ;
Cappellini, M. Domenica ;
El-Beshlawy, Amal ;
Origa, Raffaella ;
Elalfy, Mohsen ;
Kilinc, Yurdanur ;
Perrotta, Silverio ;
Karakas, Zeynep ;
Viprakasit, Vip ;
Habr, Dany ;
Constantinovici, Niculae ;
Shen, Junwu ;
Porter, John B. .
BLOOD, 2015, 125 (25) :3868-3877
[9]   The safety and acceptability of twice-daily deferiprone for transfusional iron overload: A multicentre, open-label, phase 2 study [J].
Badawy, Sherif M. ;
Kattamis, Antonis ;
Ezzat, Hatoon ;
Deschamps, Benoit ;
Sicard, Eric ;
Fradette, Caroline ;
Zhao, Feng ;
Tricta, Fernando ;
Chung Tsang, Yu ;
Sheth, Sujit ;
Piga, Antonio .
BRITISH JOURNAL OF HAEMATOLOGY, 2022, 197 (01) :E12-E15
[10]   Daily alternating deferasirox and deferiprone therapy for "hard-to-chelate" β-thalassemia major patients [J].
Balocco, Manuela ;
Carrara, Paola ;
Pinto, Valeria ;
Forni, Gian Luca .
AMERICAN JOURNAL OF HEMATOLOGY, 2010, 85 (06) :460-461